Toludesvenlafaxine
Toludesvenlafaxine is a small molecule pharmaceutical. It is currently being investigated in clinical studies.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
No data
Clinical
Clinical Trials
99 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Depressive disorder | D003866 | EFO_1002014 | F32.A | 10 | 10 | 30 | 16 | 7 | 70 |
| Major depressive disorder | D003865 | EFO_0003761 | F22 | 11 | 8 | 28 | 13 | 8 | 66 |
| Depression | D003863 | — | F33.9 | 5 | 10 | 29 | 14 | 6 | 61 |
| Hot flashes | D019584 | — | — | 2 | — | 3 | 1 | 2 | 8 |
| Dysthymic disorder | D019263 | EFO_0008623 | F34.1 | — | 1 | — | 1 | 1 | 3 |
| Anxiety disorders | D001008 | EFO_0006788 | F41.1 | — | — | 1 | 2 | — | 3 |
| Pharmacokinetics | D010599 | — | — | — | — | — | 2 | — | 2 |
| Anhedonia | D059445 | — | R45.84 | — | — | — | 1 | 1 | 2 |
| Generalized anxiety disorder | D000098647 | — | — | — | — | 1 | 1 | — | 2 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | — | — | — | 1 | — | 1 |
Show 5 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 3 | — | 1 | — | — | 4 |
| Fibromyalgia | D005356 | EFO_0005687 | M79.1 | 1 | 2 | 1 | — | — | 3 |
| Diabetic neuropathies | D003929 | EFO_1000783 | — | 1 | — | 2 | — | — | 3 |
| Myofascial pain syndromes | D009209 | EFO_1001054 | — | — | 2 | 1 | — | — | 2 |
| Diabetes mellitus | D003920 | EFO_0000400 | E08-E13 | — | 2 | 1 | — | — | 2 |
| Peripheral nervous system diseases | D010523 | — | G64 | — | — | 2 | — | — | 2 |
| Sleep initiation and maintenance disorders | D007319 | — | F51.01 | — | 1 | 1 | — | — | 1 |
| Cardiovascular diseases | D002318 | EFO_0000319 | I98 | — | 1 | 1 | — | — | 1 |
| Neoplasms | D009369 | — | C80 | — | 1 | 1 | — | — | 1 |
| Postpartum depression | D019052 | EFO_0007453 | F53.0 | — | — | 1 | — | — | 1 |
Show 2 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | — | 1 | — | — | — | 1 |
| Prediabetic state | D011236 | EFO_1001121 | R73.03 | — | 1 | — | — | — | 1 |
| Insulin resistance | D007333 | EFO_0002614 | E88.819 | — | 1 | — | — | — | 1 |
| Glucose intolerance | D018149 | HP_0000833 | R73.03 | — | 1 | — | — | — | 1 |
Indications Phases 1
No data
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Bipolar disorder | D001714 | EFO_0000289 | F30.9 | — | — | — | — | 1 | 1 |
| Acute kidney injury | D058186 | — | N17 | — | — | — | — | 1 | 1 |
| Wounds and injuries | D014947 | — | T14.8 | — | — | — | — | 1 | 1 |
| Cancer pain | D000072716 | — | G89.3 | — | — | — | — | 1 | 1 |
| Vomiting | D014839 | — | R11.1 | — | — | — | — | 1 | 1 |
| Nausea | D009325 | — | R11.0 | — | — | — | — | 1 | 1 |
| Adjustment disorders | D000275 | — | F43.2 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Toludesvenlafaxine |
| INN | toludesvenlafaxine |
| Description | Toludesvenlafaxine, also formerly known as ansofaxine and sold under the brand name Ruoxinlin, is an antidepressant which is approved for the treatment of major depressive disorder in China. It is also under development for use in other countries like the United States. It is a serotonin–norepinephrine–dopamine reuptake inhibitor (SNDRI) and was developed by Luye Pharma Group.
|
| Classification | Small molecule |
| Drug class | antianxiety, antidepressant inhibitor of norepinephrine and dopamine re-uptake |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | Cc1ccc(C(=O)Oc2ccc(C(CN(C)C)C3(O)CCCCC3)cc2)cc1 |
Identifiers
| PDB | — |
| CAS-ID | 916918-84-8 |
| RxCUI | — |
| ChEMBL ID | CHEMBL4227736 |
| ChEBI ID | — |
| PubChem CID | 56955395 |
| DrugBank | — |
| UNII ID | A7CGH459FN (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 57 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
0 adverse events reported
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use